Plasma platelet-activating factor acetylhydrolase is a dynamic variable in critical illness: In the end, is change good for you?

Critical Care Medicine

Volumn 33, Issue 6, 2005, Pages 1462-1463

  Zimmerman, Guy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Multiple organ failure; Platelet activating factor acetylhydrolase; Platelet activating factor signaling system; Sepsis; Thrombosis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; MEMBRANE PHOSPHOLIPID; RECOMBINANT ENZYME;

CRITICAL ILLNESS; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HYDROLYSIS; INTENSIVE CARE UNIT; LEUKOCYTE; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPECTIVE STUDY; SEPSIS; SIGNAL TRANSDUCTION; THROMBOCYTE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; HUMANS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 20444463514     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000166719.65161.D3     Document Type: Editorial

References (14)

1. Claus RA, Russwurm S, Dohrn B, et al: Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit Care Med 2005; 33:1416-1419
2. Stafforini DM, McIntyre TM, Zimmerman GA, et al: Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272: 17895-17898
3. Stafforini DM, McIntyre TM, Zimmerman GA, et al: Platelet activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40:1-30
4. Zimmerman GA, McIntyre TM, Prescott SM, et al: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30:5294-5301
5. Schuster DP, Metzler M, Opal Set al: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31:1612-1619
6. Opal S, Laterre PF, Abraham E, et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32: 332-341
7. Rabinocici R: Platelet activating factor inhibition in sepsis: The end? Crit Care Med 2003; 31:1861-1862
8. Minneci PC, Deans KJ, Banks SM, et al: Should we continue to target the platelet-activating factor pathway in septic patients? Crit Care Med 2004; 32:585-588
9. Stafforini DM, Mcintyre TM, Prescott SM: Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol 1990; 187:344-357
10. Grissom CK, Orme JF, Richer LD, et al: Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome. Crit Care Med 2003; 31:770-775
11. Marshall JC: Such stuff as dreams are made on: Mediator-directed therapy in sepsis. Nature Reviews/Drug Discovery 2003; 2:391-405
12. Angeli V, Liodrá J, Rong JX, et al: Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004; 21:561-574
13. Lindemann SW, Yost CC, Denis MM, et al: Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs. Proc Natl Acad Sci USA 2004; 101:7076-7081
14. Yost CC, Denis MM, Lindemann S, et al: Activated polymorphonuclear leukocytes rapidly synthesize retinoic acid receptor-α: A mechanism for translational control of transcriptional events. J Exp Med 2004; 200: 671-680